Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study

Table 3 Incidence rate and hazard ratio of irritable bowel syndrome associated with selective serotonin reuptake inhibitor use in Cox regression analysis

	SSRI use (2000-2010)						aHR2	(95%CI)	P value
	No (n = 78612)			Yes (n = 19653)
	Event	Person-years	Incidence rate of IBS1	Event	Person-years	Incidence rate of IBS
Overall	478	460307	1.04	236	108713	2.17	1.74	(1.44-2.10)	< 0.001
Sex
Female	282	270195	1.04	132	65169	2.03	1.65	(1.29-2.11)	< 0.001
Male	196	190112	1.03	104	43544	2.39	1.85	(1.38-2.48)	< 0.001
Age
< 20	8	34575	0.23	5	8564	0.58	1.12	(0.23-5.41)	0.884
20-29	27	73594	0.37	20	17815	1.12	2.78	(1.36-5.70)	0.005
30-39	61	89305	0.68	32	21416	1.49	1.95	(1.13-3.34)	0.016
40-49	96	91299	1.05	57	21899	2.60	1.79	(1.19-2.69)	0.005
50-59	85	65244	1.30	48	15508	3.10	2.17	(1.40-3.36)	< 0.001
≥ 60	201	106290	1.89	74	23511	3.15	1.32	(0.97-1.79)	0.077

¹per 1000 person-years;

²aHR, adjusted by age, sex, urbanization, family income, area of residence, occupation, anti-psychotics and the comorbidities listed in Table 1. IBS: Irritable bowel syndrome; SSRI: Selective serotonin reuptake inhibitor.